FDA grants accelerated approval to futibatinib for cholangiocarcinoma

[FDA]

On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients.


Baca selengkapnya di : http://www.fda.gov...